ConCallIQ
Go Pro
Home › Divi's Laboratories › Revenue History

Divi's Laboratories Revenue History — Quarter by Quarter

Divi's Laboratories's revenue moved from ₹1,778 Cr in Q1 FY24 to ₹2,604 Cr in Q3 FY26, a 46.5% change over 10 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

QuarterRevenue (₹ Cr)YoY Change
Q3 FY26₹2,604 Cr+12.1%
Q2 FY26₹2,715 Cr+17%
Q1 FY26₹2,410 Cr—
Q4 FY25₹2,585 Cr—
Q3 FY25₹2,319 Cr—
Q2 FY25₹2,338 Cr—
Q1 FY25₹2,118 Cr+18%
Q3 FY24₹1,855 Cr—
Q2 FY24₹1,909 Cr—
Q1 FY24₹1,778 Cr—

What management said about revenue

G

Q3 FY26 · Three dedicated CS projects to commercialize by Q3-Q4 CY2027

Three custom synthesis molecules currently in validation/regulatory approval stages are expected to start commercial volumes in the second half of calendar year 2027.

G

Q3 FY26 · Double-digit revenue growth trajectory maintained

Management reiterated expectation of double-digit constant currency growth, supported by a balanced pipeline across patent phases.

G

Q2 FY26 · Three major CS projects to commercialize in 1-2 years

Three dedicated custom synthesis projects are at various stages of validation/construction and are expected to contribute revenue within 1-2 years, subject to regulatory approvals.

G

Q2 FY26 · Constant currency revenue growth ~10.8% for H2

Management expects constant currency revenue growth for the second half to be similar to H1's 10.79%.

G

Q1 FY26 · Three Major Dedicated Projects with Long-Term Contracts

Three custom synthesis projects are underway with long-term supply commitments, expected to commercialize over the next 12-24 months.

G

Q1 FY26 · Peptide Capacity Commercialization in 12-14 Months

Solid-phase peptide synthesis capacity is expected to commercialize within 12-14 months, subject to regulatory approvals and customer timelines.

G

Q4 FY25 · Double-digit revenue growth in FY26

Management expects overall revenue to grow at a double-digit rate in FY26, driven by custom synthesis and generics.

G

Q4 FY25 · New CS contracts commercialization by late 2026/early 2027

The two long-term custom synthesis contracts announced are expected to start commercial production around Q3/Q4 2026 or early 2027, subject to regulatory approvals.

G

Q3 FY25 · Double-digit revenue growth target

Management targets double-digit revenue growth on a yearly basis, driven by custom synthesis and generics.

G

Q3 FY25 · Generics and custom synthesis to be 50-50%

The company aims for a balanced revenue mix of 50% generics and 50% custom synthesis over time.

G

Q2 FY25 · Contrast media volume growth of 20-30% YoY

Management expects year-on-year volume increase of 20-30% in contrast media, driven by long-term contracts and new qualifications.

G

Q2 FY25 · New generic launches from 2026 onwards

Multiple generic products are advancing towards customer qualifications and regulatory approvals, with revenue contributions expected from 2026.